Neogenomics Profit Margin

Neogenomics (NEO) currently reports a profit margin of -4.1% as of September 2026. That compares with -16.0% in the prior-year period — up 74.4% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Neogenomics's profit margin history and peer comparisons.

Neogenomics's profit margin increased from -16.0% to -4.1% — a 74.4% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neogenomics's profit margin of -4.1% is lower than the Healthcare sector average of 9.48%. That is roughly 143.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Neogenomics's current -4.1% should be judged against Healthcare norms (sector average: 9.48%) and against NEO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Neogenomics, and consider following NEO for alerts when major investors trade the stock.